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Abstract
Background: Although the safety of liver surgery has improved enormously, hepatic surgery continues
to face challenging complications. Therefore, improvements supported by evidence-based guidelines are
still required. The conduct of randomized controlled trials in liver surgery using dichotomous outcomes
requires a large sample size. The use of surrogate endpoints (SEPs) reduces sample size but SEPs should
be validated before use.
Aim: The aim of this review was to summarize the SEPs used in hepatic surgery related trials, their
definitions and recapitulating the evidence validating their use.
Method: A systematic computerized literature search in the biomedical database PubMed using the
MeSH terms ‘hepatectomy’ or ‘liver resection’ or ‘liver transection’ was conducted. Search was limited to
papers written in the English language and published between 1 January 2000 and 1 January 2010.
Results: A total of 593 articles met the search terms and 49 articles were included in the final selection.
Standard biochemical liver functions tests were the most frequently used SEP (32 of 49 the studies). The
used definitions of SEPs varied greatly among the studies. Most studies referred to earlier published
material to justify their choice of SEP. However, no validating studies were found.
Conclusion: Many SEPs are used in liver surgery trials however there is little evidence validating them.
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Introduction
In the last decades, liver surgery has been a constantly evolving
field and its prominent role in the treatment of primary, second-
ary, malignant or non-malignant liver diseases has been well
established.1 Although considerable improvements in mortality
and morbidity rates have been achieved in many surgical centres,
complications as a result of surgically induced liver damage still
represent challenging events.2 Consequently, trials evaluating sur-
gical techniques and therapeutic interventions with appropriate
endpoints are still needed in this field.
Randomized controlled trials (RCTs) are considered manda-
tory in evaluating the significance of clinical interventions
and their potential implementation in daily clinical practice.3
However, conducting adequately powered RCTs is frequently not
feasible in many medical fields such as hepatic surgery.4–6 In spite
of calls for more rigorous surgical research trials, the overall
number and quality of RCTs in surgery remains suboptimal.6 The
introduction of standards in reporting RCTs such as the Consoli-
dated Standards of Reporting Trials (CONSORT)7 has led to the
necessity of defining primary and, if required, secondary out-
comes.7 Thus, it is imperative to standardize the definitions of the
endpoints reported in hepatic surgery trials. Currently, the chosen
outcomes are mostly clinical endpoints and can be divided in
short- (e.g. peri-operative complications and peri-operative or
30 days mortality) and long-term outcomes (e.g. survival and
disease-free survival). Van den Broek et al. recently demonstrated
that conducting an adequately powered RCT in liver surgery using
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the clinical dichotomous outcomes mortality and morbidity was
not feasible because of the required large sample size.8The intro-
duction of surrogate endpoints (SEPs) in RCTs is considered a
potential solution for solving the problems which usually com-
promise the conduct of a sound trial such as complexity, sample
size, long-term follow-up and costs.9
A SEP is a laboratory measurement or a physical sign used as a
substitute for a clinically meaningful endpoint that measures
directly how a patient feels, functions or survives.10–12 Ideally,
changes on a SEP induced by a therapy should reflect a clinically
meaningful endpoint. In practice, this requirement frequently
fails.13 Moreover, SEPs should be validated before being used to
assess clinical outcomes. Nonetheless, validation is usually over-
looked, especially if biologically plausible grounds are given.14 In
practice, a correlation is often considered as validation for a SEP.
However, it has been demonstrated that a correlate does not make
a surrogate.13
Objectives of this paper
The aim of the present systematic review was to summarize the
SEPs representing the effect of surgically induced damage used in
liver surgery trials. Additionally, this study aimed at finding
common definitions of the used SEPs and at recapitulating the
evidence or validation justifying the use of those particular
endpoints.
Methods
Search strategy
Three authors (K.v.M., D.L. and S.O.D.) performed a systematic
computerized literature search according to the methodology rec-
ommended by the Cochrane Collaboration. The worldwide data-
base of biomedical literature PubMed was searched using the
Medical Subject headings (MeSH) terms: ‘hepatectomy’ or ‘liver
resection’ or ‘liver transection’. Additionally, the three authors
(L.M., K.v.M. and D.L.) manually reviewed all the articles’ refer-
ences lists for identification of relevant studies. Search results were
stored in an Endnote file (Endnote X2, Philadelphia, PA, USA).
Study eligibility
The search was limited to patients older than 18 years, and to
articles published between 1 January 2000 and 1 January 2010.
Exclusion criteria were non-human studies and papers published
in languages other than English. Studies were eligible if they used
SEPs as primary or secondary outcome measures. They were
excluded if they reported only on dichotomous outcomes, such as
mortality and morbidity, or only reported on survival. Papers
using outcome measures that were not considered as surrogate
markers for liver injury, i.e. the need for a blood transfusion, the
amount of operative blood loss or transection time, were also
excluded as well as studies reporting on surgical procedures other
than liver resection or assessing the effects of different therapeutic
modalities such as chemotherapy, radio-frequency ablation or
liver transplantation. Trials focusing on non-surgical interven-
tions such as imaging, the effect of portal vein embolization as
well as on liver regeneration were also excluded.
Search of evidence justifying the use of SEPs
All included studies were further scrutinized for references justi-
fying the choice of the used SEPs. All references related to the
endpoints mentioned either in the ‘introduction’ or in the ‘mate-
rials and methods’ sections were considered as references provid-
ing evidence and justification for the choice of the SEP. All
references were assessed for compliance with the Boissel criteria
for validation of SEPs.15 Briefly, SEPs were checked upon three
criteria: convenience, prediction validity and relationship with
clinical endpoint.
Data collection and analysis
Two authors (K.v.M. and L.M.) extracted the data and the results
were reviewed independently by two other authors (D.L. and
S.O.D.). Disagreements were solved by discussion. The following
data were recorded systematically after formation of the final list
of studies fulfilling the inclusion criteria: first author, year of pub-
lication, study design, number of patients, defined endpoints and
the association of defined endpoints with morbidity, mortality or
survival. The references given by the authors to explain the choice
of the surrogate endpoints were also recorded in a separate
Endnote file.
Results
Quality and quantity of evidence
A total of 593 articles met the search terms. Overall, 552 were
excluded. Of those, 320 were excluded after reading the abstracts
and 232 were excluded after reading the full text. Cross-checking
through the references of the included papers delivered an addi-
tional 8 studies, resulting in a total of 49 articles being included in
this review (Fig. 1). All studies were either RCTs or consecutive
case series. The search for references justifying the choice of end-
points delivered 125 articles. These studies were mainly reviews or
previously published clinical trials (data not shown).
Used SEPs and their definitions
Several biomarkers of hepatic functions as well as systemic param-
eters were used as SEPs (Table 1). Standard biochemical liver func-
tions tests to quantify hepatocellular damage [post-operative
plasma alanine transaminase (ALT), aspartate transaminase
(AST), gamma glutamyl transpeptidase (GGT) and alkaline phos-
phatase (AP)] were the most frequently used SEPs (32 of the 49
studies). Hepatic synthetic function quantified with various hae-
matological factors such as prothrombin time (PT) and platelets
counts was also frequently used (29 studies). Only two studies
used a single SEP. The remaining studies examined a combination
or two or more SEPs. Eleven studies did not find a correlation
between the used SEP and a clinical outcome.
The definitions of the used SEPs varied greatly among studies
(Table 2). The most frequently used SEPs (biochemical liver func-
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tion tests) were often defined as plasma peak values over a period
of 3 to 7 days post-operatively. These discrepancies in definitions
and timing of measurement of the SEPs were seen throughout
the studies included in this review (Table 2). Authors aimed at
showing a correlation between clinical outcomes (mortality
and/or morbidity) or an independent predictor factor of these
dichotomous outcomes.
Evidence justifying the choice of SEPs
A total of 26 studies referred to earlier published studies to
support their choice of SEP (Table 3). From the retrieved studies
justifying the SEP, 46% were experimental studies and 77% were
clinical studies. Only 6 studies used RCTs as a reference for the
selection of their endpoint. Of these none was a validating study
for a SEP.
Validation of the SEPs using the three criteria defined
by Boissel et al.
The used SEPs occurred more often than clinical endpoints, there-
fore complying to the first criteria described by Boissel et al.15 The
two other criteria of Boissel et al. could not be verified in this
review as they required full insight of the original data and poten-
tial follow-up of the patients.
Discussion
The present systematic literature review is an attempt at a com-
prehensive and critical evaluation of surrogate endpoints used in
liver surgery-related clinical trials. The majority of studies used
biological plausible, though not validated, surrogate outcomes. As
the liver is involved in a multitude of processes, many functions
could serve as surrogate endpoints. In line with this, many surro-
gate outcomes have been used in reporting the results of trials in
hepatic surgery. However, there was a lack in standardized defini-
tions of the most commonly used SEPs.
Liver surgery has been a subject of extensive research in the past
two decades.16 As a result, the safety and efficacy of surgical inter-
ventions have increased substantially while the indications for
performing a liver resection are continuously extending.17–20 In
spite of a decrease in mortality and morbidity rates, there is still a
need for standardized outcome parameters to evaluate therapeutic
efficacy or hazards of liver operations.21 Composite and surrogate
outcomes are considered as statistically adequate alternatives for
replacing the standard short-term dichotomous outcome of mor-
tality and morbidity in many medical fields.21–25 Formulation of
surrogate outcomes requires, first and foremost, standardization
of definitions of the used SEPs. The lack of adequate definitions of
outcomes impairs comparison and evaluation of diagnostic and
therapeutic trials. Recently, van den Broek et al.21 conducted a
survey among hepato-biliary surgeons to reach a consensus on
definitions of complications after liver surgery. These definitions
were extracted from the currently available literature and stand-
ardized by the authors before being subjected to discussion by
experts. The need for the aforementioned survey on the defini-
tions was because of the lack of uniformity on definitions as
shown in the present review. To reach a consensus on the defini-
tions of the SEPs frequently used in liver surgery related trials, a
questionnaire similar to the survey above stated should be
designed. Defining SEPs for hepatic surgery trials should take into
account the numerous targets of interventions in liver surgery-
related trials. As all the currently used SEPs are yet to be validated,
many definitions can be proposed and adapted to the different
effects expected from various interventions.
In the present comprehensive literature review, we were able to
retrieve references rationalizing the selection of SEPs used in the
majority of the studies. These references were studies using similar
endpoints either in clinical trials or in experimental settings.
Unfortunately, no study using validated SEPs was found. Valida-
tion and value of SEPs has been, and still is, a matter of debate.13,26
Prentice12 developed four criteria that are sufficient to validate a
SEP in phase three clinical trials. However, these criteria have been
considered too stringent and difficult to verify.27,28 In a compre-
hensive review, Boissel et al.15 redefined the three main criteria
that a SEP must meet to be considered as valid surrogate for a
clinical endpoint. First, a surrogate should be convenient, i.e. it
should occur more often than the corresponding clinical point.
The time course of the SEP should precede that of the clinical
endpoint so that disease or its progression can be recognized or
predicted quicker than the actual clinical endpoint using the SEP.25
Second, the relationship between the surrogate and the clinical
endpoint should be established both quantitatively and qualita-
PubMed search: liver
resection or hepatectomy
or hepatic transection or
liver transection:
593 hits
    552 articles excluded:
a) nouse of surrogate
(64)
b) effect of other
treatment, not (only) LR
(307)
- chemotherapy
- embolization
- safety surgical device
- pain control
- effect vaccination
- effect anaesthesia
- effect nutrition
c) no surgery (30)
d) no liver pathology (14)
e) imaging (18)
f) animal studies (3)
g) blood loss/transfusions
(17)
h) Others (99)
41 articles using surrogate
endpoints included
Total articles included:
49 articles
Cross references of
included papers: 8 articles
included
Figure 1 Flowchart selection articles. LR, liver resection
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tively through relevant epidemiological and clinical studies. The
nature of this relationship should be understood in terms of
pathophysiology or in terms of an expression of joint risk.25 Lastly,
a surrogate endpoint should produce parallel estimates of risks
and benefits as the clinical endpoints. The endpoints selected by
the authors in the last 10 years all seemingly comply to the first
criterion as they describe alterations either in hepatic or systemic
parameters. However, we were not able to verify if the other cri-
teria were met challenging the validity of the obtained results in
the studies included in this review. The complexity of validation is
perhaps clearly illustrated by two elegant studies which attempted
to validate surrogates for mortality following post-resectional
liver failure.29,30 Balzan et al. prospectively evaluated 704 patients
undergoing hepatic resection.29 They were able to show that the
50-50 criteria (PT <50% and serum total bilirubin >50 mmol/l on
day 5 post-operatively) were an accurate predictor of liver failure
and death after a hepatectomy. However, their findings were soon
contested byMullen et al.30 who conducted a similar study in 1059
patients undergoing major hepatectomy in which the 50-50 crite-
ria could not be reproduced. The authors therefore introduced a
new criterion (peak bilirubin >7.0 mg/dl) that should be consid-
ered as a more reliable marker predicting post-resectional liver
failure and mortality.
Several other medical fields have been trying to standardize
the outcomes that are used in clinical trials. Recently, the
National Institutes of Health (NIH) and the Agency for Health-
care Research and Quality in the United Kingdom convened an
expert group to propose which biomarkers should be assessed
as standardized asthma outcomes in future clinical research
studies.31–33 The challenging task of validating SEPs in liver
surgery related trials should follow a similar design and start by
assessing and standardizing the definitions of the most com-
monly used SEPs. It could be achieved either by the conduct of
a survey among worldwide HPB surgeons or the formation of
an experts panel as demonstrated by the NIH. As a result, a
common international prospective database with clear defini-
tions of SEPs could be established. This database would allow
the conduct of multicentre trials validating the SEPs in liver
surgery. Alternatively, a large multi-centre, multi-national pro-
spective study could be designed to validate the potentially most
valuable SEPs. As an example, the Medical Research Council
(UK) recently funded a prospective validation study of a com-
bination of the SEPs dimethyl-arginine and ischaemia modified
albumin (DASIMAR; MRC 08/H0714/8) in decompensated
cirrhosis. Moreover, a recently published study presented an
international, multicentre, external validation analysis of the
utility interval to biochemical failure (IBF) in predicting prostate
cancer mortality at the time of biochemical failure.34 IBF was
chosen as prostatic cancer progression defined by prostate-
specific antigen, otherwise known as biochemical failure (BF), is
almost always the earliest sign of recurrent prostate cancer and
can predate clinical manifestations of disease by months to years.
Earlier, a large study of 221 men who experienced BF after
radiotherapy, a shorter time interval between the completion of
treatment and BF [i.e. interval to BF (IBF)] had been shown to
be related to the development of distant metastasis and prostate
cancer mortality.35 Thereafter the extensive validation study was
designed to substantiate IBF as a SEP for identification of the
potentially lethal prostate cancer. These studies are solid exam-
ples liver surgery researchers can follow.
Table 1 Functions and events used as surrogate endpoints (SEPs)
Function and/or event
measured
Surrogate endpoints Number
of papers
using SEPs
• Hepatic parameters
Hepatocellular damage ALT, AST, GGT, AP 32
Uptake, conjugation, excretion Serum (total or conjugated) bilirubin 29
Cholestasis Alkaline phosphatase 2
Hepatic synthetic function Coagulation factors, platelets, INR, PT, glycogen content, albumin 23
Hepatic perfusion, anion excretion ICG (k), ICG-PDR 6
Hepatic anaerobe metabolism Transhepatic oxygen pressure gradient, hepatic oxygenation, transhepatic
lactate gradient
2
Hepatocyte urea synthesis capacity Ammonia 1
• Systemic parameters
Oxidative stress SOD, MDA, MPO, gluthatione, gluthatione disulfide 6
Anaerobe metabolism Lactate, pyruvate 6
Inflammation Cytokines, PMNL activation, CRP 12
Apoptosis Caspases, Bcl2, beclin-1 1
ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl transpeptidase; AP, alkaline phosphatse; INR, international normal-
ized ratio; PT, prothrombin time; ICG, indocyanine green; SOD, superoxide dismutase; MDA, malondialdehyde; MPO, myeloperoxidase; PMNL,
polymorphonuclear leucocyte; CRP, C-reactive protein.
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Table 2 Surrogate endpoints and definitions used
First author, year Liver-related SEP (primary
or secondary)
Timepoints of
measurement and
definition endpoint
Taura, 201036 Portal and hepatic veins pressures; hepatic
artery and portal vein blood flow; lactate;
bilirubin, INR
Haemodynamic, oxygenation and liver functions at the time
of abdominal closure, liver function also peak value over
PODs 1, 2 and 4
Pietsch, 201037 Lactate and pyruvate levels in arterial and
hepatic venous blood and hepatic oxygenation
Values during liver manipulation, 15 min after hilus
occlusion, 10 min after end of LR, at the time of
abdominal closure and on POD 1
Domart, 200938 Caspases 3,8,9, Bcl2, beclin-1, light chain type II
expressions, vacuoles; ALT, AST, bilirubin, AP,
GGT, PT
Values just prior to IP and after liver reperfusion and liver
function on POD 7
Xia, 200939 ALT, AST, bilirubin, HA, IL-6 Peak values over 1, 3 and 7 PODs
de Liguori, 200940 ICG PDR, PLF; AST, ALT, bilirubin Correlation between ICG PDR and onset PLF; correlation
ICG PDR and AST, ALT, bilirubin on PODs 1, 5, 10
Arkadopoulos, 200941 AST, bilirubin, PT, IL-6, IL-8, MDA Liver function: daily till discharge; IL: at 12, 24 and 48 h
after LR; MDA: 5 min prior to occlusion and 1 h after
reperfusion
Wen, 200942 ALT, T-bilirubin Values over postoperative course
Beck-Schimmer, 200843 AST and ALT Peak AST and ALT over 7 PODs
Akita, 200844 ICG-R15 and T-bilirubin ICG-R15 (after opening abdomen, during clamping phase
and at abdomen closure) and peak T-bil over
hospitalization period
Ko, 200845 TLV, graft volume, RLV, AST, ALT, T-Bil, PT,
albumin, blood urea nitrogen
Values after closure abdomen and over PODs 1, 2, 3, 5, 7
and 30
Scheingraber, 200846 ICG PDR, PT and bilirubin Peak over 7 PODs
Kim, 200747 ALT, AST, Tbil, IL-6 IL-6: values before and after 30 min Pringle, and liver
function tests: values over postoperative course
Pulitano, 20072 PT-INR, AT III, mean platelet count, fibrinogen,
D-dimer, platelets count; IL-6, TNF-a
Values over PODs 1, 2 and 5
Tang, 200248; 200749 Glycogen, MDA and ATP content, SOD activity;
AST, ALT, AKP
Glycogen content: before occlusion, ATP, MDA and SOD:
after occlusion and after 1 hr reperfusion, Liver functions:
PODs 1 and 5
Brooks, 200750 Partial pressure carbon dioxide in liver tissue,
partial pressure oxygen, bilirubin, ALT
Pressures after 10 min clamping and 5 min reperfusion or
10 min clamp and 20 min reperfusion, Liver function:
POD 2
Mullen, 200730 Bilirubin, INR Peak bilirubin and INR over 90 days
Kostopanagiotou, 200751 Fibronectin Concentration on POD 1
Schmidt, 200752 IL-6, IL-8, IL-10, TNF-a, HLA-DR, LPS-induced
TNF-a, CRP
Mean values over PODs 1, 2, 3 and 7
Petrowsky, 200653 AST, ALT, bilirubin and PT Peak values and area under the curve over 5 PODs
Kostopanagiotou, 200654 MDA AST, PT and bili MDA: values 5 min after reperfusion, at the end of LR and
on PODs 1, 3 and 6, Liver function: On PODs 1, 3 and 6
Theodoraki, 200655 Lactate, transhepatic lactate gradient,
transhepatic oxygen pressure gradient
Values 50 min after reperfusion
Dunschede, 200656 Lactate, CHE, AST, ALT and ATP content Lactate, CHE, ATP content, ALT and AST: opening
abdomen, 30 min ischaemia, 30 min reperfusion, POD1,
AST, ALT: peak PODs 1–3
Esaki, 200657 Bilirubin ration calculated as serum T-bil on
POD2 divided by preoperative level; PT, AST,
ALT
Values over 10 PODs
Azoulay, 200658 AST, ALT, T-bil, GST, PT ALT: peak over PODs 1, 7, 30 (primary endpoint), GST, AST
(peak), PT, T-bil: values over PODs 1, 7 and 30
Kim, 200659 IL-6; AST, ALT, PT, Tbil, ICG R15 IL-6: after LR but before reperfusion, at closure abdomen
and on POD1, Liver function: Peak over PODs 1, 3 and 7
Sugimoto, 200660 ICG-K values, T-bil, albumin Values over PODs 1, 2, 3, 5 and 7, Liver function: on POD1
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In an attempt to define and validate SEPs in hepatic surgery
trials, caution should be taken in the choice of SEPs considering
the different types of hepatic surgery that can be studied and the
patient population that is being investigated.
Conclusions
The present systematic review showed that many SEPs are used in
hepatic surgery related research. Although these endpoints are
Table 2 Continued
First author, year Liver-related SEP (primary
or secondary)
Timepoints of
measurement and
definition endpoint
Balzan, 200529 Bilirubin and PT Values at over 7 PODs
Figueras, 200561 ALT, AST, lactate, PT, bilirubin Liver function: over PODs 1, 2, 3, 5 and 6, Lactate: at the
beginning of mobilization, after 10 min reperfusion
Chouker, 200562 PMNL activation, MPO, IL-6, IL-8, ALT PMNL: 3, 15, 30, 120 min after LR, POD1, MPO: 30 min
after LR, ALT: on PODs 1, 2; IL-6, IL-8: 30, 60 min after
LR and POD1
Chouker, 200563 ALT, AST, a-GST Values at 3, 15, 30, 60 min, 24 h and 48 h after LR
Kaiho, 200564 Ammonia Values over 5 PODs
Bartels, 200465 ALT, AST Values over PODs 1, 10, 30 min after reperfusion, 6, 12 h
after ICU admission, PODs 1, 2, 4 and 6
Li, 200466 AST, ALT, T-bil, albumin, caspase-3 activity,
TUNEL assay
Values over PODs 1, 3 and 7
Nishiyama, 200467 ALT, AST, T-bil, albumin, AKP, CHE, PT and
platelet count
Values over PODs 1, 3 and 7
Nuzzo, 200468 AST, ALT, bilirubin, PT Values over PODs 1, 3 and 7
Clavien, 200369 AST, ALT, bilirubin, PT, hepatic ATP Peak AST and ALT over 7 PODs; ATP: 30 min after
reperfusion
Smyrniotis, 200370 PT, bilirubin, AST, ALT; IL-6, IL-8; MDA Liver function : Peak over PODs 1 to 6; Cytokines: 3, 12, 24
and 48 h after LR; MDA: 30 min after reperfusion
Wu, 200371 IL-6, endostatin Values over 2, 4, 8 h and PODs 1, 3, 5, 7, 9
Capussotti, 200372 AST, ALT, Tbil Peak over PODs 1, 3 and 7
Man, 200373 ET1 expression, eNOS and iNOS activity Correlation between ET-1 and eNOS activity with hepatic
ultrastructural changes
Muratore, 200374 IL-6, AST, ALT IL-6: 1, 4 and 24 h after LR; Liver function: 1, 4 and 24 h
after LR
Tang, 200248 Glycogen, ATP and MDA contents, SOD activity,
AST, ALT, AKP
At the end of the vascular occlusion and 1 h after
reperfusion; Liver function: values over PODs 1 and 5
Vriens, 200275 MDA, glutathione, glutathione disulfide, vitamin C
liver enzymes and blood clotting factors
–
Kim, 200276 ALT, AST, bilirubin, TNF-a, IL-1b, IL-6 Liver function: values over PODs 1, 3 and 7; Cytokines:
laparotomy, at completion of parenchymal transection,
1 h post reperfusion
Okochi, 200277 T-bil, platelet, AST, ALT, PT, ICGk Values over PODs 1, 2, 3, 5 and 7
Wiezer, 200178 Plasma amino acid patterns, coagulation and
fibrinolytic cascade systems and neutrophil
functions
–
Orii, 200179 ALT, AST, ICGk, lactate Values just after reperfusion and 1 h after reperfusion; Liver
function: values over 1 h after LR, PODs 1 and 3
Noie, 200180 AST, Tbil, alb, PT; UTI-urinary trypsin inhibitor in
plasma pUTI and urine uUTI, CRP
Values over postoperative course
Yamashita, 200181 IL-6, IL-10 peritoneal and venous Values over 0, 6, 12 h after reperfusion and on PODs 1, 3
and 7
ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma glutamyl transpeptidase; AP, alkaline phosphatse; INR, international normal-
ized ratio; PT, prothrombin time; ICG, indocyanine green; ICG PDR, indocyanine green plasma disappearance rate; SOD, superoxide dismutase; MDA,
malondialdehyde; MPO, myeloperoxidase; PMNL, polymorphonuclear leucocyte; CRP, C-reactive protein; IL, interleukin; HA, hyaluronic acid; LR, liver
resection; POD, postoperative day; IP, intermittent pringle manoeuver; PLF, post-resectional liver failure; TLV, total liver volume; RLV, rest liver volume;
CHE, cholinesterase.
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Table 3 Studies used as references for the choice of the surrogate endpoints (SEPs)
First author, year References for validation of
SEPs
Characterization of studies
used as references
Taura, 201036 No specific mention of validating studies No specific mention of validating studies
Pietsch, 201037 No specific mention of validating studies No specific mention of validating studies
Domart, 200938 No specific mention of validating studies No specific mention of validating studies
Xia, 200939 No specific mention of validating studies No specific mention of validating studies
de Liguori, 200940 SEPs adopted from an earlier trial RCT
Arkadopoulos, 200941 No specific mention of validating studies No specific mention of validating studies
Wen, 200942 No specific mention of validating studies No specific mention of validating studies
Beck-Schimmer, 200843 SEPs adopted from clinical and experimental studies RCTs and experimental studies
Akita, 200844 No specific mention of validating studies No specific mention of validating studies
Ko, 200845 No specific mention of validating studies No specific mention of validating studies
Scheingraber, 200846 No specific mention of validating studies No specific mention of validating studies
Kim, 200747 No specific mention of validating studies No specific mention of validating studies
Pulitano, 20072 SEPs adopted from earlier trials RCT and consecutive case series
Tang, 200749 SEP adopted from earlier trials Experimental studies
Brooks, 200750 SEPs adopted from earlier trials Observational clinical studies and experimental studies
Mullen, 200730 SEP initially adopted an earlier trial RCT
Kostopanagiotou, 200751 SEP adopted from a review Review
Schmidt, 200752 No specific mention of validating studies No specific mention of validating studies
Petrowsky, 200653 SEPs adopted from earlier trials RCTs
Kostopanagiotou, 200654 No specific mention of validating studies No specific mention of validating studies
Theodoraki, 200655 No specific mention of validating studies No specific mention of validating studies
Dunschede, 200656 SEPs adopted from earlier trials Experimental study and clinical study
Esaki, 200657 SEPs adopted from clinical experience No study was used but clinical experience
Azoulay, 200658 SEPs adopted from earlier studies Clinical studies and an experimental study
Kim, 200659 SEP adopted from earlier studies Experimental and clinical studies
Sugimoto, 200660 SEPs adopted from earlier trials Several clinical studies (RCTs and consecutive case series)
Balzan, 200529 SEPs adopted from two trials RCTs
Figueras, 200561 SEPs adopted from earlier trials Clinical studies
Chouker, 200562 No specific mention of validating studies No specific mention of validating studies
Chouker, 200563 SEPs adopted from earlier studies Clinical trials and experimental studies
Kaiho, 200564 No specific mention of validating studies No specific mention of validating studies
Bartels, 200465 No specific mention of validating studies No specific mention of validating studies
Li, 200466 SEPs adopted from an earlier trial RCT
Nishiyama, 200467 No specific mention of validating studies No specific mention of validating studies
Nuzzo, 200468 SEPs adopted from an earlier trial RCT
Clavien, 200369 SEP adopted from an earlier trial Non-randomized pilot study
Smyrniotis, 200370 SEP adopted from earlier studies Experimental and clinical studies
Wu, 200371 SEPs adopted from earlier trials Experimental studies
Capussotti, 200372 No specific mention of validating studies No specific mention of validating studies
Man, 200373 SEPs adopted from earlier studies Experimental and clinical studies
Muratore, 200374 SEPs adopted from earlier studies Experimental and clinical studies
Tang, 200248 No specific mention of validating studies No specific mention of validating studies
Vriens, 200275 No specific mention of validating studies No specific mention of validating studies
Kim, 200276 SEPs adopted from earlier studies Experimental studies
Okochi, 200277 SEP adopted from an earlier trial Clinical study
Wiezer, 200178 No specific mention of validating studies No specific mention of validating studies
Orii, 200179 SEPs adopted from earlier studies Several clinical studies in the transplantation setting
Noie, 200180 No specific mention of validating studies No specific mention of validating studies
Yamashita, 200181 SEPs adopted from an earlier trial Clinical trial
RCT, randomized controlled trial.
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biologically plausible, there is little evidence on their validity as
true surrogates of clinical endpoints. It is important to standardize
SEPs definitions and validate the SEPs used in liver surgery trials
as the safety is steadily increasing making the differences between
interventions smaller and therefore leading to enormous sample
sizes. Validated SEPs could be reliable surrogates of clinical
endpoints.
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